EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

No Increase in Blood Pressure Assessed With the 24‐h Holter Monitoring in Patients With Episodic Migraine During Early Treatment With Anti‐ CGRP Monoclonal Antibodies: A Prospective Observational Study ( SAFHYPER )

Flavia Lo Castro, Niccolò Bonini, Luigi Francesco Iannone, Alberto Boccalini, Daria Brovia, Luca Pani, Giuseppe Boriani, Simona Guerzoni

European Journal of Neurology · 2025-09 · 32 (9)

DOI: 10.1111/ene.70351 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Neurology, online erschienen am 06.09.2025. Verfasst von Flavia Lo Castro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology an…. Hauptthemen laut MEDLINE: Migraine Disorders, Blood Pressure, Antibodies, Monoclonal, Calcitonin Gene-Related Peptide. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Migraine is associated with an increased cardiovascular risk, including hypertension. Anti‐calcitonin gene related peptide (CGRP) monoclonal antibodies (mAbs) are effective preventive treatments, but concerns have been raised about their potential hypertensive effects. Herein, we assess the early changes in blood pressure (BP) during anti‐CGRP mAbs treatment in patients with migraine using 24‐h Holter monitoring.

Methods

We conducted a prospective, real‐world study including 20 patients with episodic migraine (EM) during the early treatment with anti‐CGRP mAbs. Participants underwent 24‐h Holter BP monitoring before treatment and 4 weeks after the first injection. The primary outcome was the change in mean systolic BP (SBP). Secondary outcomes included changes in diastolic BP (DBP), differential BP, diurnal/nocturnal values, heart rate (HR), and dipping patterns.

Results

Mean 24‐h SBP and DBP showed non‐significant differences after treatment (−2.4 mmHg and −1.8 mmHg, p = 0.075). No significant changes were observed in diurnal BP, but a significant reduction in nocturnal DBP was detected (−2.6 mmHg, p = 0.026). Consistently, the proportion of patients with a physiological dipping profile increased from 45.0% to 85.0% post‐treatment ( p = 0.008). HR remained unchanged, and no patients had mean PAD ≥ 130/80. No adverse events were reported.

Conclusion

Anti‐CGRP mAbs did not induce clinically relevant BP increases in the early treatment phase and were associated with improved nocturnal DBP and a favorable shift in dipping profile in patients with EM. These findings suggest the short‐term cardiovascular safety of anti‐CGRP mAbs, though further studies with larger cohorts and longer follow‐up are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Migraine DisordersBlood PressureAntibodies, MonoclonalCalcitonin Gene-Related PeptideHumansFemaleMaleAdultProspective StudiesMiddle AgedElectrocardiography, AmbulatoryBlood Pressure Monitoring, Ambulatory

Stichwörter der Autor:innen

CGRPcardiovascular eventshypertensionmigrainesafety

Substanzen

Antibodies, MonoclonalCalcitonin Gene-Related Peptide

Autor:innen und Institutionen

  • Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy.
  • Cardiology Division, AOU Policlinico di Modena, Modena, Italy.
  • Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy.
  • Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, Florida, USA.

Zitieren

APA

Lo Castro, F., Bonini, N., Iannone, L. F., Boccalini, A., Brovia, D., Pani, L., Boriani, G., & Guerzoni, S. (2025). No Increase in Blood Pressure Assessed With the 24‐h Holter Monitoring in Patients With Episodic Migraine During Early Treatment With Anti‐ CGRP Monoclonal Antibodies: A Prospective Observational Study ( SAFHYPER ). European Journal of Neurology, 32(9). https://doi.org/10.1111/ene.70351

Vancouver

Lo Castro F, Bonini N, Iannone LF, Boccalini A, Brovia D, Pani L, et al. No Increase in Blood Pressure Assessed With the 24‐h Holter Monitoring in Patients With Episodic Migraine During Early Treatment With Anti‐ CGRP Monoclonal Antibodies: A Prospective Observational Study ( SAFHYPER ). European Journal of Neurology. 2025;32(9). doi:10.1111/ene.70351

BibTeX
@article{LoCastro2025,
  author = {Lo Castro, Flavia and Bonini, Niccolò and Iannone, Luigi Francesco and Boccalini, Alberto and Brovia, Daria and Pani, Luca and Boriani, Giuseppe and Guerzoni, Simona},
  title = {No Increase in Blood Pressure Assessed With the 24‐h Holter Monitoring in Patients With Episodic Migraine During Early Treatment With Anti‐ CGRP Monoclonal Antibodies: A Prospective Observational Study ( SAFHYPER )},
  journal = {European Journal of Neurology},
  year = {2025},
  volume = {32},
  number = {9},
  doi = {10.1111/ene.70351}
}
Kostenlos starten →